Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

908 Devices Reports Second Quarter 2024 Financial Results and Reiterates 2024 Revenue Outlook

MASS

Revenue increases 16% compared to prior year, driven by newly acquired handheld products

908 Devices Inc. (Nasdaq: MASS), a pioneer of purpose-built handheld and desktop devices for chemical analysis, today reported financial results for the quarter ended June 30, 2024.

"We delivered solid execution on a multitude of fronts in the quarter, including the acquisition and integration of RedWave Technology into our company. With an expanded handheld portfolio, we are now supporting both our new and existing forensics customers more efficiently,” said Kevin J. Knopp, CEO and Co-founder. “We also maintained a strong focus on operational excellence during the quarter and have begun to see early benefits of our increasing scale.”

Recent Highlights

  • Revenue of $14.0 million for the second quarter 2024, increasing 16% compared to the second quarter 2023
    • Handheld revenue was $11.1 million, increasing 26% year over year
    • Desktop revenue was $2.9 million, decreasing 9% year over year
    • Recurring revenue was $5.3 million, increasing 33% year over year
    • 38% of revenue was recurring revenue, driven by service and REBEL consumables
  • Gross margin increased 490 basis points to 53% for the second quarter 2024, partly due to timing of production but also as a result of scale across the business including higher handheld service revenues
  • Launched a quantification package that enhances our XplorIR handheld gas and vapor analyzer, enabling first responders to now identify and quantify nearly 5,000 airborne chemicals
  • Completed the commercial integration of RedWave Technology
  • Presented 13 posters at the American Society for Mass Spectrometry (ASMS) conference and were collaborators on three oral presentations with researchers from the University of Wisconsin-Madison and the National Institute for Bioprocessing Research and Training (NIBRT)
  • Appointed Michele M. Leonhart, former administrator of the U.S. Drug Enforcement Administration, to our Board of Directors

Second Quarter 2024 Financial Results

Revenue was $14.0 million for the three months ended June 30, 2024, a 16% increase over the prior year period. This was primarily driven by an increase in handheld devices revenue offset by a decrease in desktop devices revenue. The installed base grew to 3,067 devices with 143 handheld devices and 10 desktop devices placed during the second quarter 2024. Recurring revenue represented 38% of total revenues in the quarter.

Gross profit was $7.4 million for the second quarter of 2024, compared to $5.8 million for the corresponding period in the prior year. Gross margin was 53% as compared to 48% for the corresponding prior year period. Adjusted gross profit was $8.1 million for the second quarter of 2024, compared to $6.0 million for the corresponding period in the prior year. Adjusted gross margin was 58% as compared to 50% for the corresponding prior year period.

Operating expenses were $21.0 million for the second quarter of 2024, compared to $16.7 million for the corresponding prior year period. This increase was driven by $1.9 million in acquisition and integration costs, the inclusion of two months of operating expenses related to our RedWave acquisition, and stock-based compensation.

Net loss was $12.5 million for the second quarter of 2024, compared to $9.3 million for the corresponding prior year period. Adjusted EBITDA was a loss of $7.3 million for the second quarter of 2024, compared to a loss of $7.7 million for the second quarter of 2023.

Cash, cash equivalents and marketable securities were $77.4 million as of June 30, 2024 with no debt outstanding.

2024 Guidance

908 Devices continues to expect full year reported 2024 revenue to be in the range of $63.0 million to $65.0 million, representing 25% to 29% growth over full year 2023. This includes $11 million of expected revenue from RedWave Technology, representing 8 months of ownership.

Webcast Information

908 Devices will host a conference call to discuss the second quarter 2024 financial results before market open on Tuesday, August 6, 2024 at 5:30 am Pacific Time / 8:30 am Eastern Time. A webcast of the conference call can be accessed at https://ir.908devices.com/news-events/events. The webcast will be archived and available for replay for at least 90 days after the event.

About 908 Devices

908 Devices is revolutionizing chemical analysis with its simple handheld and desktop devices, addressing life-altering applications. The Company’s devices are used at the point-of-need to interrogate unknown and invisible materials and provide quick, actionable answers to directly address some of the most critical problems in forensics, bioprocessing, pharma / biopharma, life sciences research and adjacent markets. The Company is headquartered in the heart of Boston, where it designs and manufactures innovative products that bring together the power of complementary analytical technologies, microfluidic sampling and separations, software automation, and machine learning.

Non-GAAP Measures of Financial Performance

To supplement the Company’s financial statements, which are presented on the basis of U.S. generally accepted accounting principles (GAAP), the following non-GAAP measures of financial performance are included in this release and presented with detailed reconciliations to comparable GAAP financial results in the tables below:

  • Adjusted Gross Profit is defined as gross profit excluding intangible amortization, acquisition and integration costs, restructuring charges (including the costs of severance), and non-cash expenses related to stock-based compensation.
  • Adjusted Gross Margin is defined as Adjusted Gross Profit expressed as a percentage of total revenue.
  • Adjusted EBITDA is defined as net loss excluding other income, benefit for income taxes, depreciation, intangible amortization, acquisition and integration costs, restructuring charges (including the costs of severance), non-cash expenses related to stock-based compensation, and costs associated with contingent consideration related to the Company’s acquisitions and for which the conditions for payment have not yet been achieved.

The Company’s non-GAAP financial results presented in this earnings release exclude certain costs that management believes do not have a direct correlation to future business operations, nor do the resulting charges recorded accurately reflect the performance of ongoing operations for the period in which such charges are recorded, nor do the resulting charges recorded accurately reflect the anticipated cash flows of ongoing operations, and as such, excluding these costs allows management to understand and evaluate core operating performance and trends. However, as there are no standardized methods of calculating these non-GAAP financial measures, the Company’s methods may differ from those used by other companies in its industry, and accordingly, the use of these measures may not be directly comparable to similar measures used by others, thus limiting their usefulness for purposes of comparison. Furthermore, these non-GAAP measures have certain limitations since they do not include the impact of certain expenses and cash flows that are reflected in the Company’s GAAP financial results. Accordingly, when analyzing the Company’s operating performance and guidance, investors should not consider non-GAAP measures in isolation or as a substitute for, or superior to, comparable financial measures prepared in accordance with GAAP. Rather, the Company believes that these non-GAAP financial measures, when viewed in addition to and not in lieu of reported GAAP financial results, provide investors with additional meaningful information to assess financial performance and trends, enable comparison of financial results between periods, and allow for greater transparency with respect to key metrics utilized internally in analyzing and operating the Company’s business.

Forward Looking Statements

This press release includes “forward looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts are forward-looking statements, including, without limitation, statements regarding the Company’s future revenue and growth. Words such as “may,” “will,” “expect,” “plan,” “anticipate,” “estimate,” “intend” and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. These forward-looking statements are based on management’s current expectations and involve known and unknown risks, uncertainties and assumptions which may cause actual results to differ materially from any results expressed or implied by any forward-looking statement, including the risks outlined under “Risk Factors” and elsewhere in the Company’s filings with the Securities and Exchange Commission which are available on the SEC's website at www.sec.gov. Additional information will be made available in our annual and quarterly reports and other filings that we make from time to time with the SEC. Although the Company believes that the expectations reflected in its forward-looking statements are reasonable, it cannot guarantee future results. The Company has no obligation, and does not undertake any obligation, to update or revise any forward-looking statement made in this press release to reflect changes since the date of this press release, except as may be required by law.

908 DEVICES INC.
Condensed Consolidated Statements of Operations
(in thousands, except share and per share amounts)
(unaudited)

Three Months Ended

Six Months Ended

June 30,

June 30,

2024

2023

2024

2023

Revenue:

Product revenue

$

10,266

$

9,595

$

17,499

$

16,617

Service revenue

3,681

2,354

6,439

4,594

Contract revenue

100

145

100

370

Total revenue

14,047

12,094

24,038

21,581

Cost of revenue:

Product cost of revenue

4,732

4,800

7,942

8,586

Service cost of revenue

1,823

1,448

3,601

2,718

Contract cost of revenue

74

52

74

99

Total cost of revenue

6,629

6,300

11,617

11,403

Gross profit

7,418

5,794

12,421

10,178

Operating expenses:

Research and development

6,381

5,525

12,171

10,923

Selling, general and administrative

14,597

11,208

26,498

23,211

Total operating expenses

20,978

16,733

38,669

34,134

Loss from operations

(13,560

)

(10,939

)

(26,248

)

(23,956

)

Other income, net

943

1,522

2,644

1,955

Loss from operations before income taxes

(12,617

)

(9,417

)

(23,604

)

(22,001

)

Benefit for income taxes

69

71

139

122

Net loss

$

(12,548

)

$

(9,346

)

$

(23,465

)

$

(21,879

)

Net loss per share attributable to common stockholders

$

(0.37

)

$

(0.29

)

$

(0.70

)

$

(0.68

)

Weighted average common shares outstanding

34,061,933

32,199,156

33,386,413

32,083,122

908 DEVICES INC.
Condensed Consolidated Balance Sheets
(in thousands)
(unaudited)

June 30,

December 31,

2024

2023

Assets

Current assets:

Cash, cash equivalents and marketable securities

$

77,383

$

145,682

Accounts receivable, net

10,987

8,989

Inventory

18,589

14,938

Prepaid expenses and other current assets

3,485

4,181

Total current assets

110,444

173,790

Operating lease, right-of-use assets

5,904

6,233

Property and equipment, net

3,556

3,342

Goodwill

40,220

10,367

Intangible, net

47,298

7,860

Other long-term assets

1,352

1,389

Total assets

$

208,774

$

202,981

Liabilities and Stockholders' Equity

Current liabilities:

Accounts payable and accrued expenses

$

7,610

$

9,904

Deferred revenue

11,954

10,629

Operating lease liabilities

2,153

2,016

Total current liabilities

21,717

22,549

Deferred revenue, net of current portion

9,528

3,929

Other long-term liabilities

21,170

11,012

Total liabilities

52,415

37,490

Total stockholders' equity

156,359

165,491

Total liabilities and stockholders' equity

$

208,774

$

202,981

908 DEVICES INC.
Reconciliations of GAAP to Non-GAAP Financial Measures
(Unaudited, amounts in thousands, except percentage and per share data)
In all tables below, totals may not add due to rounding

Reconciliation from Gross Profit (GAAP) to Adjusted Gross Profit (Non-GAAP) and Margin Percentage:

Three Months Ended

Six Months Ended

June 30,

June 30,

2024

2023

2024

2023

Gross Profit (GAAP)

$

7,418

$

5,794

$

12,421

$

10,178

Intangible amortization

530

107

637

213

Acquisition and integration costs

-

-

-

-

Restructuring

-

-

-

-

Stock-based compensation

202

140

373

255

Adjusted Gross Profit (Non-GAAP)

$

8,150

$

6,041

$

13,431

$

10,646

Gross Margin Percentage (GAAP)

53

%

48

%

52

%

47

%

Adjusted Gross Margin Percentage (Non-GAAP)

58

%

50

%

56

%

49

%

Reconciliation from Net Loss (GAAP) to Adjusted EBITDA (Non-GAAP):

Three Months Ended

Six Months Ended

June 30,

June 30,

2024

2023

2024

2023

Net Loss (GAAP)

$

(12,548

)

$

(9,346

)

$

(23,465

)

$

(21,879

)

Adjustments:

Other income, net

(943

)

(1,522

)

(2,644

)

(1,955

)

Benefit for income taxes

(69

)

(71

)

(139

)

(122

)

Depreciation

500

368

918

738

Intangible amortization

693

219

913

437

Acquisition and integration costs

1,950

-

1,950

-

Restructuring

-

-

-

524

Stock-based compensation

3,096

2,578

5,739

4,744

Contingent consideration

-

65

-

230

Adjusted EBITDA (Non-GAAP)

$

(7,321

)

$

(7,709

)

$

(16,728

)

$

(17,283

)